JUNS
Jupiter Neurosciences, Inc.
There isn't enough reported data to score JUNS yet.
JUNS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
JUNS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
JUNS PE Valuation
JUNS has no meaningful PE right now: it lost money over the past year.
JUNS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect JUNS's losses to shrink, with revenue growing.
JUNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$18.33 | -$4.14 |
| Q1 2026 | -$19.50 | -$11.27 |
| Q4 2025 | -$18.75 | -$12.83 |
| Q3 2025 | -$17.94 | -$14.65 |
| Q2 2025 | -$14.19 | -$7.36 |
| Q1 2025 | -$8.23 | +$1.21 |
| Q4 2024 | -$5.92 | +$5.44 |
| Q2 2022 | -$38.70 | -$21.74 |
JUNS is still losing money, but far less than before: $18.33 per share over the past year, against $39.92 at its worst in early 2022.
JUNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $233.3K | -12% |
JUNS's revenue is growing: $24,245 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11313% | N/A |
| Q1 2026 | -10524% | N/A |
| Q2 2022 | -297% | +31 points |
| Q2 2021 | -328% | N/A |
| Q1 2021 | -61% | N/A |
| Q4 2020 | -45% | N/A |
JUNS's operating margin was −11313% last quarter, down 11252 points from the same quarter a year ago, near the bottom of its range since 2020.
JUNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.3M | -$1.5M |
| Q1 2026 | -$1.4M | -$369.1K |
| Q4 2025 | -$2.4M | +$1.3M |
| Q2 2025 | -$828.2K | -$720.8K |
| Q1 2025 | -$1.1M | -$997.9K |
| Q4 2024 | -$3.7M | -$3.5M |
| Q2 2024 | -$107.5K | -$49.5K |
| Q1 2024 | -$65.2K | +$33.5K |
JUNS has burned cash in almost every quarter: −$7M over the past year, against −$6M the year before.
JUNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +87.5K shares |
| 1 year | +26% | +115K shares |
| 3 years | +27% | +119K shares |
| 5 years | +371% | +439K shares |
JUNS has 557,567 diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q2 2022 | — |
| Q1 2022 | — |
JUNS Net Leverage
JUNS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JUNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.2 | Neutral |
| Stochastic | 0.9 | Oversold |
JUNS's weekly RSI is 32 (neutral) and its Stochastic is 1 (oversold).
JUNS PE vs Healthcare Sector
JUNS has no meaningful PE right now: it lost money over the past year.
JUNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.51 | 26% below |
| 20 week MA | $5.49 | 66% below |
| 50 week MA | $27.4 | 93% below |
| 100 week MA | $83.4 | 98% below |
JUNS is in a downtrend: it's below all four of its weekly moving averages, and 98% below its 100-week average.
JUNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $584.3 | $826.5 | +41% |
| 2025 | $826.5 | $85.5 | -90% |
| 2026 YTD | $85.5 | $1.86 | -98% |
JUNS has finished lower in one of the last two years. It's down 98% so far in 2026.